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The presence of synaptic proteins involved in excitation/secretion c upling was examined in ten small cell lung cancer lines. N-Type calcium channels 
(co-conotoxin receptors), synaptotagmin (p65) and syntaxin (HPC-1) were detected in eight. Co-immunoprecipitation experiments indicated that 
syntaxin can form a complex with synaptotagmin a d calcium channels. The expression of synaptotagmin in small cell lung cancer may elicit an 
autoimmune response that reduces transmitter release at the nerve terminal. 
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1. INTRODUCTION 
Rapid exocytosis at nerve terminals is thought to 
require docking of synaptic vesicles at plasma mem- 
brane release sites in close proximity to calcium chan- 
nels, a process that presumably involves protein pro- 
tein interaction [1-3]. Recent evidence suggests that 
docking is mediated by synaptotagmin (p65), a synaptic 
vesicle protein that can form a ternary complex with 
two plasma membrane proteins: the N-type calcium 
channel and syntaxin (alternatively termed HPC-1 or 
synaptocanalin) [4~9]. 
Small cell lung cancer (SCLC), the most malignant of 
human lung tumors, displays neurosecretory character- 
istics [10,11]. These include the expression of voltage- 
gated calcium channels [12-14] and the synaptic vesicle 
glycoprotein synaptophysin [11], and the release of neu- 
ropeptides uch as bombesin/gastrin-releasing peptide, 
which are important autocrine growth factors [15]. In 
some cases the expression of neural antigens by the 
tumor initiates production of autoantibodies which then 
react with homologous targets in the nervous system, 
resulting in autoimmune disease. Lambert Eaton my- 
asthenic syndrome (LEMS) is the best-characterized 
neurological disorder of this kind. LEMS autoantibod- 
ies reduce presynaptic calcium influx and acetylcholine 
release at the neuromuscular junction, consequently 
leading to muscle weakness (reviewed in [161). 
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We have recently shown that LEMS IgG contains an 
anti-synaptotagmin specificity and hypothesized that 
these antibodies may inhibit neurotransmitter r lease by 
binding to a synaptotagmin/calcium channel complex 
[5]. If synaptotagmin is a relevant antigen in LEMS, one 
would predict its presence in SCLC. The present report 
examines the expression of synaptotagmin a d syntaxin 
and their coupling to N-type calcium channels to form 
a putative docking complex in a panel of SCLC lines. 
2. EXPERIMENTAL 
2.1. Materials" 
c0-Conotoxin GVIA (o)CgTx) was purchased from the Peptide Insti- 
tute (Osaka). The monoclonal antibodies, 1D12 and 10H5, were pre- 
pared and purified as previously described [4,7]. The monoclonal anti- 
synaptophysin antibody, 171B5, was provided by Dr. S.C. Fujita 
(Mitsubish Kasei Institute for Life Science). Goat anti-mouse IgG 
peroxidase conjugates were from Biosys, and enhanced chemilumines- 
cence (ECL) Western blotting detection reagents were from Amer° 
sham. 
2.2. Tissue preparation 
Crude rat brain synaptosomes (P2) were prepared by differential 
centrifugation. SCLC xenografts were prepared as previously de- 
scribed [17] and stored in liquid N2. Minced fragments were homoge- 
nized in 10 mM Tris, 0.32 M sucrose adjusted to pH 7.4 with HC1 
containing the protease inhibitors 0.2 mM phenylmethylsulfonyl fluo- 
ride, 2/~M pepstatin A, and 1 mM iodoacetamide, using an Ultra- 
turrax apparatus. After a 10 min centrifugation at 600 x g, the result- 
ing supernatant was centrifuged at 100,000 x g for 45 min and the 
membrane pellet collected. Protein was assayed by the BCA method 
(Pierce) with a bovine serum albumin standard. 
2.3. [1251]m-Conotoxin binding 
Monoiodo[125I](oCgTx (2,200 Ci/mmol) was prepared and purified 
by HPLC [18]. Binding assays, containing 100fig of SCLC membrane 
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Fig. 1. [125I]co-Conotoxin binding to small cell lung cancer membranes. SCLC 82 membranes were incubated with (a) a range of [~251]mCgTx 
concentrations, in the presence ( , )  and in the absence (I) of 0.1/tM unlabeled mCgTx, or (b) 30 pM [~25I]oJCgTx in the absence and in the presence 
of a range of unlabeled mCgTx concentrations. After filtration and three washes, bound [~25I]mCgTx was measured by ?'-counting. 
protein in 0.5 ml of binding buffer (25 mM Tris, 0.15 M NaC1, 0.2% 
BSA adjusted to pH 7.4 with HCI), were incubated with the indicated 
concentrations of [1251]mCgTx + unlabeled mCgTx for 60 min at 37 ° C. 
Binding was terminated by rapid vacuum filtration over Whatman 
GF/C filters pretreated with 0.3% polyethyleneimine and 3 washes 
with 2 ml of ice-cold binding buffer. Bound ligand was measured by 
y-counting. 
2.4. lmmunoblotting 
Proteins were separated by SDS-PAGE on 10% acrylamide gels, 
transferred to a nitrocellulose membrane, blocked with 10% low-fat 
milk in Tris-buffered saline, and probed with the mAbs, 1D12, 10H5, 
or control mouse IgG (5 mg/ml). ECL detection was carried out with 
anti-mouse IgG peroxidase. 
2.5. Immunoprecipitation 
Rat brain P2 or SCLC membranes were labeled by incubation with 
0.1 nM [I25I]ogCgTx, washed by centrifugation and solubilized in 1% 
CHAPS, 0.32 M sucrose, 10 mM Tris adjusted to pH 7.4 with HCI. 
After centrifugation at 100,000 x g to eliminate insoluble material, the 
supernatant was incubated for 4 h at 4°C in the presence of 30/~g of 
mAb 1D12 of 10H5 in a final volume of 100 ,ul. Pre-swollen protein 
A-Sepharose CL-4B (4 mg dry weight) was added and samples were 
rotated for 1 h at 4°C. The tubes were centrifuged for 2 min at 
10,000 x g and pellets were washed in 1 ml 0.4% CHAPS, 25 mM Tris, 
0.15 M NaCI, adjusted to pH 7.4 with HCI. Immunoprecipitated 
radioactivity was then measured by T-counting. Results were ex- 
pressed as % immunoprecipitation, taking as 100% the cpm corre- 
sponding to the ligand/receptor complex, i.e. the cpm retained on 
Whatmann GF/B filters pretreated with 0.3% polyethyleneimine. 
3. RESULTS AND DISCUSSION 
N-Type calcium channels which are involved in exci- 
tation/secretion coupling at certain synaptic terminals 
are selectively blocked by co-conotoxin GVIA 
(mCgTx). N-Type Ca channels were detected in SCLC 
membranes as receptors for [~25I]mCgTx. A specific 
binding component was demonstrated from saturation 
curves (Fig. la) and from competition with increasing 
concentrations of unlabeled coCgTx (Fig. lb). 
[125I](oCgTx binds irreversibly to its receptor on the Ca 
channel and conventional Scatchard analysis cannot 
therefore be used to measure the equilibrium dissocia- 
tion constant or the receptor capacity [18]. The data 
presented in Fig. la and b indicate 50% receptor occu- 
pation at 30 pM coCgTx. The binding site density esti- 
mated from the plateau level of the saturation curve 
(Fig. 1 b) was 13 fmol/mg of protein in membranes of the 
SCLC 82 line. The expression of [J2sI]coCgTx receptors 
by ten different SCLC lines was examined by binding 
assays at a single saturating concentration (0.1 nM) of 
[I25I]coCgTx in the presence and absence of 0.1 tiM na- 
tive (oCgTx (Table I). Although specific binding was 
Table 1 
Co-expression of N-type calcium channels, synaptotagmin and syn- 
taxin in small cell lung cancer lines 
Cell line co-Conotoxin Synaptotagmin Syntaxin 
receptor 
(fmol/mg/protein) 
SCLC 82 13.7 ++ ++ 
SCLC l0 13.6 ++ ++ 
SCLC 61 10.1 ++ ++ 
SCLC 74B 10 ++ + 
SCLC 91 9.5 ++ + 
SCLC 41 8.5 ++ + 
SCLC 74A 7.9 + + 
SCLC 6 4.7 + + 
SCLC 75 1.5 ND ND 
SCLC 95 ND ND ND 
The relative intensity of immunoreactive bands in Western blots was 
scored as ++ or +; ND = not detected. 
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Fig. 2. Expression of synaptotagmin a d syntaxin small cell lung cancer. Immunoblots of rat brain synaptosomes (lane l, 50 pg protein) and SC LC 
membranes (lanes 2 13,250 pg protein) were probed with anti-synaptotagmin Ab 1D 12 (lanes 1 5), control mouse IgG (lanes 6 9) or anti-syntaxin 
mAb 10H5. (SCLC 61 = lanes 2, 6 and 10; SCLC 91 = lanes 3, 7 and 11; SCLC 6 = lanes 4, 8 and 12; SCLC 10 -- lanes 5, 9 and 13). 
clearly detected in 8 out of 10 lines, at similar levels to 
those reported in human neuroblastoma membranes 
[14], receptor density was about 50- times less than in 
rat brain nerve terminals [18]. 
Western blots of SCLC membranes were probed with 
1 2 34  
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Fig. 3. Association of synaptotagrnin with syntaxin-1 in small cell lung 
cancer. CHAPS extracts of SCLC 82 membranes were incubated with 
control mouse IgG (lanes 1, 3) or anti-syntaxin mAb 10H5. Immune 
complexes were recovered on protein A-Sepharose CL4B and the 
presence of syntaxin and synaptotagmin was examined by probing 
immunoblots of the immunoprecipitated proteins with mAb 10H5 
(lanes 1, 2) and mAb 1D12 (lanes 3, 4). The intense immunoreactivity 
present in all lanes, both at the entry to the resolving gel and at 
approximately 50 kDa, corresponds to immunoblogulins u ed in the 
immunoprecipitation step that are subsequently detected by the sec- 
ondary anti-mouse IgG antibody. 
monoclonal antibodies against synaptotagmin a d syn- 
taxin. A representative experiment is illustrated in Fig. 
2. Synaptotagmin was detected as a 65 kDa band in 
SCLC and rat brain synaptosomes (Fig. 2, lanes 1 5). 
Immunoreactive bands at approximately 46and 37 kDa 
were consistently seen in both tissues. These are thought 
to be proteolytic fragments, produced either in vivo or 
during membrane preparation. No immunoreactivity 
was detected in control experiments with non-immune 
mouse IgG (Fig. 2, lanes 6-9). The same tumors also 
expressed syntaxin migrating as a 35 kDa band (Fig. 2, 
lanes 10 13). 
Eight out of ten SCLC lines expressed both synapto- 
tagmin and syntaxin. These proteins were not detected 
in SCLC 75 and 95, which also had the lowest density 
of [~25I]coCgTx binding sites. These two lines did, how- 
ever, display some neuroendocrine characteristics, as 
both contained synaptophysin detected by Western 
blotting (not shown). 
In nerve terminals yntaxin is thought o be involved 
in docking synaptic vesicles at exocytotic sites via its 
interaction with synaptotagmin. We therefore xamined 
whether synaptotagmin associates with syntaxin in 
SCLC by co-immunoprecipitation experiments (Fig. 3). 
When CHAPS-solubilized SCLC 82 membranes were 
immunoprecipitated with mAb 10H5, syntaxin (Fig. 3, 
lane 2) and synaptotagmin (Fig. 3, lane 4) were identi- 
fied in immunoblots of the recovered proteins. Note 
that a fraction of syntaxin in Fig. 3, lane 2, migrates at 
67 kDa. This band presumably represents a dimeric 
form of the 35 kDa protein. Syntaxin contains four 
heptad motifs [6,7] that are thought o be involved in 
protein protein interactions and the formation of 
homo-oligomers, even after SDS denaturation, has been 
reported [7]. Neither syntaxin or synaptotagmin were 
detected in experiments in which the immunoprecipi- 
tating antibody was replaced by control mouse IgG 
(Fig. 3, lanes 1 and 3). Syntaxin can therefore associated 
with synaptotagmin in SCLC. 
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Fig. 4. Association of syntaxin with N-type calcium channels in small 
cell lung cancer. CHAPS-solubilized [~2sI](oCgTx-labeled calcium 
channels from SCLC 82 membranes were incubated with monoclonal 
anti-synaptotagmin (1D12), and anti-syntaxin (10H5) antibodies and 
control mouse IgG. Immune complexes were recovered on protein 
A-Sepharose, and precipitated [~zSI]o)CgTx receptors were measured 
by g-counting (+ S.E.M., n = 3). 
Immunoprecipitation experiments with solubilized 
[LzSI]o)CgTx receptors from rat brain membranes have 
shown that a population of N-type calcium channels 
forms a ternary complex with synaptotagmin a d syn- 
taxin [9,10]. We therefore asked whether mAbs 1D12 
and 10H5 immunoprecipitate N-type calcium channels 
from SCLC 82 membranes. Specific immunoprecipita- 
tion of a fraction of CHAPS-solubilized N-type calcium 
channels (about 20%) was consistently observed with 
anti-syntaxin antibodies but not with anti-synaptotag- 
min antibodies (Fig. 4). Low receptor density and solu- 
bilization yield in SCLC membranes imposed the use of 
relatively low concentrations of labeled antigen in these 
assays. Signal-to-background ratio was consequently 
poor, which may preclude detection of low levels of 
specific immunoprecipitation, however, parallel assays, 
performed with [125I]o)CgTx receptors olubilized from 
synaptic membranes and diluted to the same antigen 
concentration, did indicate significant immunoprecipi- 
tation by both mAbs 1D12 and 10H5 (Fig. 4). Although 
we have not directly demonstrated the presence of ter- 
nary complex, the data presented in Figs. 3 and 4 allow 
us to conclude that both synaptotagmin a d N-type 
calcium channels can associate with syntaxin in SCLC 
membranes. 
Recent evidence suggests that in nerve terminals yn- 
aptotagmin and syntaxin may play a role in locating 
synaptic vesicles near to the voltage-gated calcium 
channels that control transmitter release [5,7,8]. Synap- 
totagmin is a transmembrane synaptic vesicle protein 
that is a putative calcium sensor in exocytosis [20,21]. 
Synaptotagmin associates with N-type calcium chan- 
nels [5] in a complex with syntaxin [7,8], and this inter- 
action may locate vesicles in a zone accessible to rapid 
calcium transients. 
The detection of these key components of the neuro- 
secretory pathway in SCLC may be relevant to certain 
paraneoplastic autoimmune diseases of the nervous ys- 
tem. Patients with LEMS show reduced acetylcholine 
release as a consequence of the production of autoanti- 
bodies directed against calcium channel-associated pro- 
teins [16,22]. We have recently reported that some 
LEMS IgG contain an anti-synaptotagmin specificity 
[5]. The intravesicular N-terminal domain of synapto- 
tagmin is exposed at the cell surface during exocytosis, 
and LEMS IgG may inhibit neurotransmitter r lease by 
binding to a synaptotagmin/syntaxin/calcium channel 
complex via this region. Our present results demon- 
strate that a large number of SCLC lines co-express 
synaptotagmin, syntaxin, and N-type calcium channels. 
Furthermore, syntaxin interacts with synaptotagmin 
and associates with calcium channels, as described in 
synaptic terminals. These findings are compatible with 
the hypothesis that the immune response in some LEMS 
patients i directed against synaptotagmin expressed by 
SCLC. 
The production of autoantibodies against compo- 
nents of the secretory pathway may have other implica- 
tions. Many patients with paraneoplastic neurological 
disease of autoimmune origin show extended survival, 
and regression of SCLC has been documented [23]. The 
antibodies that produce the neurological syndrome may 
therefore have anti-tumoral ctivity. SCLC growth is 
sustained by autocrine secretion of neuropeptides, such 
as bombesin/gastrin eleasing peptide [15]. An interest- 
ing possibility to explore is that autoantibodies that 
inhibit exocytosis n the nervous ystem by binding to 
synaptotagmin a d/or calcium channels, may also inter- 
fere with the autocrine secretory pathway in the tumor 
itself. 
Acknowledgements: We thank Cecile Raymond for technical assis- 
tance and Dr. S.C. Fujita for the gift of 171B5 antibody. This research 
was funded by grants from Bayer Pharma, the Association Fran~aise 
contre les Myopathies, and the Assistance Publique de Marseille. 
REFERENCES 
[l] Almers, W. and Tse, F.W. (1990) Neuron 4, 813 818. 
[2] Smith, S.J. and Augustine, G.J. (1988) Trends Neurosci. 11,458 
464. 
[3] Kelly, R.B. (1993) Cell 72, Neuron 10 (Suppl.) 43 53. 
[4] Takahashi, M., Arimatsu, Y., Fujita, S., Fujimoto, Y., Kondo, 
S., Hama, T. and Miyamoto, E. (1991) Brain Res. 551,279 292. 
[5] Leveque, C., Hoshito, T., David, R, Shoji-Kassai, Y., Leys, K., 
Omori, A., Lang, B., El Far, O., Sato, K., Martin-Moutot, N., 
Newsom-Davis, J., Takahashi, M. and Seagar, M.J. (1992) Proc. 
Natl. Acad. Sci. USA 89, 3625 3629. 
[6] Inoue, A. and Akagawa, K. (1992) J. Biol. Chem. 267, 10613 
10619. 
138 
Volume 326, number 1,2,3 FEBS LETTERS July 1993 
[7] Yoshida, A., Oho, C., Omori, A., Kuwahara, R., Ito, T. and 
Takahashi, M. (1992) J. Biol. Chem. 267, 24925 24928. 
[8] Bennet, M.K., Calakos, N. and Scheller, R. (1992) Science 257, 
255-259. 
[9] Morita, T., Mori, H., Sakimura, K., Mishina, M., Sekine, Y., 
Tsugita, A., Odani, S., Horikawa, H., Saisu, H. and Abe, T. 
(1992) Biomed. Res. 13, 357-364. 
[10] Carney, D.N. (1992) Lancet 339, 843-846. 
[11] Aletsee-Ulfrecht, M.C., Langley, K., Rotsch, M., Havemann, K.
and Gratzl, M. (1990) FEBS Lett. 267, 295 300. 
[12] Roberts, A., Perera, S., Lang, B., Vincent, A. and Newsom- 
Davis, J. (1985) Nature 317, 737 739. 
[13] De Aizpurua, H.J., Lambert, E.H., Griesmann, G.E., Olivera, 
B.M. and Lennon, V.A. (1988) Cancer Res. 48, 4719-4724. 
[14] Oguro-Okana, M., Griesmann, G.E., Wieben, E.D., Slaymaker, 
S.J., Snutch, T.R and Lennon, V.A. (1992) Mayo. Clin. Proc. 67, 
1150-1159. 
[15] Cuttitta, F., Carney, D.N., Mulshine, J., Moody, T.W., Fedorko, 
J., Fischler, A. and Minna, J.D. (1985) Nature 316, 823-826. 
[16] Vincent, A., Lang, B. and Newsom-Davis, J. (1989) Trends Neu- 
rosci. 12, 496-502. 
[17] Thomas, F., Arvelo, F., Antoine, E., Jacrot, M. and Poupon, 
M.F. (1992) Cancer Res. 52, 4872-4877. 
[18] Marqu6ze, B., Martin-Moutot, N., Levaque, C. and Couraud, F. 
(1988) Mol. Pharmacol. 34, 87-90. 
[19] Sher, E., Pandiella, A. and Clementi, F. (1988) FEBS Lett. 235, 
178 182. 
[20] Perin, M.S., Fried, V.A., Mignery, G.A., Jahn, R. and Sudhof, 
T.C. (1990) Nature 345, 260 263. 
[21] Brose, N., Petrenko, A.G., Sudhof, T.C. and Jahn, R. (1992) 
Science 256, 1021-1025. 
[22] Sher, E., Gotti, C., Canal, N., Scopetta, C., Piccolo, G., Evoli, 
A. and Clementi, F. (1989) Lancet ii, 640 643. 
[23] Darnell, R.B. and De Angelis, L.M. (1993) Lancet 341, 21 22. 
139 
